Taspoglutide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Clinical trial supplies were stored refrigerated at 2-8 degrees C. As taspoglutide never reached commercial availability, no official storage guidelines were published.
Protocol Quick-Reference
Type 2 diabetes mellitus (discontinued; never approved)
Dosing
Amount
10-20 mg
Frequency
Once weekly
Duration
24-52 weeks (clinical trial protocols)
Administration
Route
SCSchedule
Once weekly
Timing
Zinc-based depot formulation forming a slow-release reservoir at the injection site. Development halted in September 2010.
Cycle
Duration
24-52 weeks
Repeatable
Single cycle
โ๏ธ Suggested Bloodwork (4 tests)
HbA1c
When: Baseline
Why: Baseline glycemic control assessment
Fasting blood glucose
When: Baseline and periodic
Why: Monitor glycemic response
Anti-drug antibodies
When: Periodic
Why: Monitor for immunogenicity (49% antibody formation rate observed)
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Liver and kidney function baseline
๐ก Key Considerations
- โDevelopment was terminated by Roche in September 2010 due to unacceptable safety signals; never approved for clinical use
- โHigh rates of nausea (53-59%), vomiting (33-37%), injection-site reactions, and systemic hypersensitivity
- โAnti-taspoglutide antibodies detected in 49% of patients, indicating high immunogenicity
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Type 2 Diabetes (T-emerge Phase 3 Protocol - Low Dose) | 10 mg subcutaneous injection once weekly. Used in the T-emerge 2 trial versus exenatide twice daily. | Once weekly subcutaneous injection | 24-52 weeks in clinical trials | Never approved for clinical use. HbA1c reduction of -1.24% in T-emerge 2. Lower dose had somewhat fewer GI side effects than 20 mg. |
| Type 2 Diabetes (T-emerge Phase 3 Protocol - High Dose) | 20 mg subcutaneous injection once weekly. The higher dose used across T-emerge trials. | Once weekly subcutaneous injection | 24-52 weeks in clinical trials | Never approved for clinical use. HbA1c reduction of -1.31% in T-emerge 2. Greater nausea and vomiting rates (59% nausea, 37% vomiting) compared to 10 mg dose. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Taspoglutide was supplied as a zinc-based depot suspension for subcutaneous injection. Specific reconstitution details were not widely published as the drug never reached market. The zinc formulation required careful preparation to ensure uniform suspension.
Recommended Injection Sites
- โAbdomen
- โThigh
๐งStorage Requirements
Clinical trial supplies were stored refrigerated at 2-8 degrees C. As taspoglutide never reached commercial availability, no official storage guidelines were published.
Community Dosing Protocols
Compare these clinical doses with what 5+ community members report using.
Based on 5+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Important Disclaimer#
Taspoglutide was never approved for clinical use. Development was terminated by Roche in September 2010 due to unacceptable safety signals. The dosing information below is derived exclusively from published clinical trial protocols and is provided for educational and research reference purposes only.
Clinical Trial Dosing#
T-emerge Phase 3 Doses#
Two dose levels were evaluated in the T-emerge clinical trial program:
| Parameter | Low Dose | High Dose |
|---|---|---|
| Dose | 10 mg | 20 mg |
| Frequency | Once weekly SC | Once weekly SC |
| HbA1c reduction (T-emerge 2) | -1.24% | -1.31% |
| Nausea rate | 53% | 59% |
| Vomiting rate | 33% | 37% |
Both doses were administered as a once-weekly subcutaneous injection using a zinc-based depot formulation.
Dose Selection Rationale#
The 10 mg and 20 mg doses were selected based on phase 2 dose-finding studies that identified these as the optimal range for glycemic control. Both doses provided clinically meaningful HbA1c reduction, with the 20 mg dose offering a modest incremental benefit at the cost of higher gastrointestinal adverse event rates.
Administration#
Taspoglutide was administered as a once-weekly subcutaneous injection. The zinc-based depot formulation formed a slow-release reservoir at the injection site, providing sustained peptide release over the 7-day dosing interval.
Injection Technique#
- Administered subcutaneously into the abdomen or thigh
- The zinc-peptide complex formed a depot at the injection site
- Injection-site reactions were a significant clinical issue, likely related to the depot formation and local immune responses
Comparison to Modern GLP-1 Agonists#
Taspoglutide's dosing frequency (once weekly) was equivalent to semaglutide (Ozempic/Wegovy) and albiglutide (Tanzeum), but its dose escalation requirements and tolerability were significantly worse. Modern GLP-1 agonists achieve once-weekly dosing through molecular modifications (acylation, albumin fusion) rather than depot formulations, resulting in better tolerability and fewer injection-site reactions.
Storage#
Clinical trial supplies were stored under refrigerated conditions. As taspoglutide was never commercialized, no standardized storage guidelines exist from regulatory agencies.
Dosing Context#
Taspoglutide belongs to the Metabolic category of research peptides. Dosing protocols for Taspoglutide are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for Taspoglutide:
Type 2 Diabetes (T-emerge Phase 3 Protocol - Low Dose)#
Dose: 10 mg subcutaneous injection once weekly. Used in the T-emerge 2 trial versus exenatide twice daily.
Frequency: Once weekly subcutaneous injection
Duration: 24-52 weeks in clinical trials
Never approved for clinical use. HbA1c reduction of -1.24% in T-emerge 2. Lower dose had somewhat fewer GI side effects than 20 mg.
Type 2 Diabetes (T-emerge Phase 3 Protocol - High Dose)#
Dose: 20 mg subcutaneous injection once weekly. The higher dose used across T-emerge trials.
Frequency: Once weekly subcutaneous injection
Duration: 24-52 weeks in clinical trials
Never approved for clinical use. HbA1c reduction of -1.31% in T-emerge 2. Greater nausea and vomiting rates (59% nausea, 37% vomiting) compared to 10 mg dose.
Reconstitution and Preparation#
Taspoglutide was supplied as a zinc-based depot suspension for subcutaneous injection. Specific reconstitution details were not widely published as the drug never reached market. The zinc formulation required careful preparation to ensure uniform suspension.
Injection Sites#
Recommended injection sites for Taspoglutide include:
- Abdomen
- Thigh
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Clinical trial supplies were stored refrigerated at 2-8 degrees C. As taspoglutide never reached commercial availability, no official storage guidelines were published.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Taspoglutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.